Privately held specialty pharmaceuticals firm Omthera Pharmaceuticals (Bedminster, NJ) has announced the results of tests it performed comparing its Epanova omega-3 fatty acid drug for high triglycerides to leading omega-3 drug Lovaza. The company says results show that Epanova was significantly more bioavailable than Lovaza.
Privately held specialty pharmaceuticals firm Omthera Pharmaceuticals (Bedminster, NJ) has announced the results of tests it performed comparing its Epanova omega-3 fatty acid drug for high triglycerides to leading omega-3 drug Lovaza. The company says results show that Epanova was significantly more bioavailable than Lovaza.
The 54-subject, randomized, open-label, four-way crossover pharmacokinetics study compared the bioavailability of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in Epanova and Lovaza, with each drug taken as single 4-g dose combined with either low- or high-fat diets, over 24 hours. The company says that specifically, test results for the subjects on a low-fat diet and taking Epanova showed EPA and DHA plasma levels that were four times higher compared to those taking Lovaza. High-fat-diet subjects also showed higher EPA and DHA levels with Epanova compared with Lovaza. Omthera says that a separate analysis also showed Epanova had a 13-fold bioavailability increase over Lovaza in subjects on the low-fat diet.
The company attributes the differences to the fact that Epanova is a free-fatty-acid form of EPA and DHA, while Lovaza is an ethyl ester EPA and DHA form. It says that free fatty acids are the chemical form in which essential fatty acids are absorbed in the digestive tract. By comparison, ethyl esters require enzymatic conversion prior to absorption, and that the release of these pancreatic enzymes requires the intake of fat-containing food as a trigger.
“The ECLIPSE [Epanova Compared to Lovaza in a Pharmacokinetic Single-Dose Evaluation] study demonstrates that Lovaza is poorly absorbed in patients on a low-fat diet,” stated Michael Davidson, MD, chief medical officer and cofounder of Omthera. “We believe that this finding will have significant clinical importance because patients with sever hypertriglyceridemia should be maintained on a low-fat diet.”
Omthera says it plans to begin a Phase 3 clinical trial soon to evaluate the effects of Epanova in high-triglyceride patients.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.